KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash & Equivalents (2019 - 2025)

Royalty Pharma's Cash & Equivalents history spans 7 years, with the latest figure at $618.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 33.4% year-over-year to $618.7 million; the TTM value through Dec 2025 reached $618.7 million, down 33.4%, while the annual FY2025 figure was $618.7 million, 33.4% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $618.7 million at Royalty Pharma, down from $938.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $2.2 billion in Q2 2023 and bottomed at $477.0 million in Q4 2023.
  • The 5-year median for Cash & Equivalents is $1.0 billion (2022), against an average of $1.3 billion.
  • The largest annual shift saw Cash & Equivalents skyrocketed 898.21% in 2021 before it tumbled 72.12% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $1.5 billion in 2021, then grew by 11.01% to $1.7 billion in 2022, then plummeted by 72.12% to $477.0 million in 2023, then skyrocketed by 94.76% to $929.0 million in 2024, then plummeted by 33.4% to $618.7 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Cash & Equivalents are $618.7 million (Q4 2025), $938.9 million (Q3 2025), and $631.9 million (Q2 2025).